Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 9/20 | 1.00 |
| ▸ | RXRB | P28702 | 5/20 | 0.48 |
| ▸ | RXRA | P19793 | 4/20 | 0.48 |
| ▸ | RXRG | P48443 | 3/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956632 | 0.88 | SLC22A12 (0.78) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL955065 | 0.88 | SLC22A12 (0.78) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL1584528 | 0.85 | SLC22A12 (0.74) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL1081012 | 0.85 | SLC22A12 (0.74) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL1584507 | 0.84 | SLC22A12 (0.72) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL957978 | 0.81 | SLC22A12 (0.68) | SLC22A12FFAR1 | |
| SCHEMBL1584589 | 0.81 | SLC22A12 (0.67) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL954556 | 0.81 | SLC22A12 (0.68) | SLC22A12FFAR1FFAR4 | |
| SCHEMBL7897205 | 0.80 | SLC22A12 (0.67) | SLC22A12RXRBRXRARXRGFFAR1 | |
| SCHEMBL1584592 | 0.80 | SLC22A12 (0.66) | SLC22A12RXRBRXRARXRGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | claimed |
| US-8829058-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-09-09 | — | — | US | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| EP-2488020-B1 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2488020-A1 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012033720-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011046800-A1 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | FPR1, FFAR1, GLS | SLC22A12 740/4885RXRB 482/4885RXRA 439/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | SLC22A12 139/4885RXRB 542/4885RXRA 603/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | SLC22A12 257/4885RXRB 989/4885RXRA 951/4885 |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | FPR1, FFAR1, GLS | SLC22A12 740/4885RXRB 482/4885RXRA 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.